Muutke küpsiste eelistusi

Antidepressants: From Biogenic Amines to New Mechanisms of Action 1st ed. 2019 [Kõva köide]

Edited by , Edited by
  • Formaat: Hardback, 442 pages, kõrgus x laius: 235x155 mm, kaal: 846 g, 8 Illustrations, color; 9 Illustrations, black and white; XII, 442 p. 17 illus., 8 illus. in color., 1 Hardback
  • Sari: Handbook of Experimental Pharmacology 250
  • Ilmumisaeg: 17-Jun-2019
  • Kirjastus: Springer Nature Switzerland AG
  • ISBN-10: 3030109488
  • ISBN-13: 9783030109486
Teised raamatud teemal:
  • Kõva köide
  • Hind: 141,35 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 166,29 €
  • Säästad 15%
  • Raamatu kohalejõudmiseks kirjastusest kulub orienteeruvalt 2-4 nädalat
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
Antidepressants: From Biogenic Amines to New Mechanisms of Action 1st ed. 2019Suurem pilt
  • Formaat: Hardback, 442 pages, kõrgus x laius: 235x155 mm, kaal: 846 g, 8 Illustrations, color; 9 Illustrations, black and white; XII, 442 p. 17 illus., 8 illus. in color., 1 Hardback
  • Sari: Handbook of Experimental Pharmacology 250
  • Ilmumisaeg: 17-Jun-2019
  • Kirjastus: Springer Nature Switzerland AG
  • ISBN-10: 3030109488
  • ISBN-13: 9783030109486
Teised raamatud teemal:
Püsilink: https://www.kriso.ee/db/9783030109486.html
Märksõnad:

This volume reviews the known neurobiology of depression and combines classic data on antidepressant treatments with modern theory on the physiology of depression. It also discusses novel mechanism of action drugs.

Part I Overview and General Principles
Impact, Diagnosis, Phenomenology, and Biology
3(34)
William Coryell
Part II The Past: From Antiquity to 1970 Including TCAs and MAOIs
Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look?
37(14)
Ravikumar Chockalingam
Britt M. Gott
Charles R. Conway
Part III The Present: 1970 to 2016
Clinical Implications of the STAR*D Trial
51(50)
A. John Rush
Shailesh (Bobby) Jain
Pharmacogenomics and Biomarkers of Depression
101(14)
Manish K. Jha
Madhukar H. Trivedi
Therapeutic Drug Monitoring of Antidepressants
115(20)
Najla Fiaturi
David J. Greenblatt
Selective Serotonin Reuptake Inhibitors
135(10)
Dee Lochmann
Tara Richardson
Serotonin and Norepinephrine Reuptake Inhibitors
145(36)
Richard C. Shelton
Neurostimulation Therapies
181(44)
Nicholas T. Trapp
Willa Xiong
Charles R. Conway
Current Role of Herbal and Natural Preparations
225(30)
David Mischoulon
Mark Hyman Rapaport
Part IV The Future
Role of Inflammation in Depression and Treatment Implications
255(32)
Jennifer C. Felger
NMDA Antagonists for Treatment-Resistant Depression
287(20)
Nuri B. Farber
Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development
307(18)
Sheldon H. Preskorn
Other Antidepressants
325(34)
T. E. Schwasinger-Schmidt
M. Macaluso
Part V Use of Antidepressants in Special Populations
Use of Antidepressants in Patients with Co-occurring Depression and Substance Use Disorders
359(12)
Theadia L. Carey
Treatment of Depression in Women
371(18)
Christina Bourne
Laura Kenkel
Management of Late-Life Depression
389(26)
J. Craig Nelson
The Use of Antidepressants in Bipolar Depression
415
John L. Beyer